Cas no 114915-14-9 (7,10-o-Ditroc docetaxel)
7,10-o-Ditroc docetaxel Chemical and Physical Properties
Names and Identifiers
-
- Docetaxel intermediate
- INTERMEDIATE FOR DOCETAXEL
- IntermediateIIIforDocetaxel
- INTERMEDIATEOFDOCETAXEL
- N-1 Step intermediate
- (aR,bS)-beta-[[(1,1-Dimethylethoxy)carbonyl]amino]-alpha-hydroxy-benzenepropanoic acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
- 7,10-O-ditroc docetaxel
- 10-deacetyl-7,10-diTroc-baccatin III
- 2H-1-Benzopyran-4-ol,2-phenyl-,acetate
- 4-acetoxy-2-phenyl-2H-1-chromene
- 4-acetoxy-2-phenyl-2H-chromene
- 7,10-Ditro-Docetaxel
- 7,11-Ditroc-docetaxel
- 7,10-Di Troc Docetaxel
- Docetaxel InterMediate (N-1)
- (aR,bS)-beta-[[(1,1-DiMethylethoxy)carbonyl]aMino]-alpha-hydroxy-benzenepropanoic acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
- 915D149
- [(1S,2S,3S,4S,7R,9S,10S,12R,15S)-4-Acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl
- C49H55Cl6NO18
- QTCVMFMWHTVJTQ-LNJGEEBYSA-
- O164
- [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-Acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl
- F12957
- 7,10-Di(trichloroethoxyformyl) docetaxel
- Benzenepropanoic acid,b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxy-,12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,[2aR-[2aa,4b,4ab,6b,9a(aR*,bS*),11a,1
- 114915-14-9
- [(1S,2S,3S,4S,7R,9S,10S,12R,15S)-4-Acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-9,12-bis(2,2,2-trichloroethoxycarbonyloxy)-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
- 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; 7,10-Bis(2,2,2-trichloroethoxycarbonyl)docetaxel
- AKOS027327928
- DS-12004
- 7,10-O-Ditrocdocetaxel
- 7,10-o-Ditroc docetaxel
-
- MDL： MFCD09839023
- Inchi： 1S/C49H55Cl6NO18/c1-24-28(69-39(61)33(58)32(26-15-11-9-12-16-26)56-40(62)74-43(3,4)5)20-47(65)37(72-38(60)27-17-13-10-14-18-27)35-45(8,36(59)34(31(24)44(47,6)7)71-42(64)68-23-49(53,54)55)29(70-41(63)67-22-48(50,51)52)19-30-46(35,21-66-30)73-25(2)57/h9-18,28-30,32-35,37,58,65H,19-23H2,1-8H3,(H,56,62)/t28-,29-,30+,32-,33+,34+,35+,37-,45+,46-,47+/m0/s1
- InChI Key： QTCVMFMWHTVJTQ-CCONUVRMSA-N
- SMILES： ClC(COC(=O)O[C@H]1C[C@@H]2[C@@](CO2)([C@@H]2[C@@H]([C@@]3(C[C@@H](C(C)=C([C@H](C([C@@]21C)=O)OC(=O)OCC(Cl)(Cl)Cl)C3(C)C)OC([C@@H]([C@H](C1C=CC=CC=1)NC(=O)OC(C)(C)C)O)=O)O)OC(C1C=CC=CC=1)=O)OC(C)=O)(Cl)Cl
Computed Properties
- Exact Mass: 807.34700
- Monoisotopic Mass: 1155.155
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 18
- Heavy Atom Count: 74
- Rotatable Bond Count: 21
- Complexity: 2180
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 9
- Undefined Atom Stereocenter Count : 2
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 7.3
- Topological Polar Surface Area: 255
Experimental Properties
- Color/Form: No data avaiable
- Density: 1.503
- Melting Point: No data available
- Boiling Point: 1064.656°C at 760 mmHg
- Flash Point: 597.682°C
- Refractive Index: 1.607
- PSA: 224.45000
- LogP: 3.65050
- Vapor Pressure: No data available
7,10-o-Ditroc docetaxel Security Information
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P280-P305+P351+P338
- Safety Instruction： H303+H313+H333
- Storage Condition：Sealed in dry,Room Temperature
7,10-o-Ditroc docetaxel Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | O94820-5g |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 5g |
￥2834.0 | 2024-07-19 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | O94820-100mg |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 100mg |
￥126.0 | 2024-07-19 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | O94820-250mg |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 250mg |
￥406.0 | 2024-07-19 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | O94820-1g |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 1g |
￥772.0 | 2024-07-19 | |
| Chemenu | CM195411-1g |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 1g |
$153 | 2021-06-09 | |
| Chemenu | CM195411-5g |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 5g |
$552 | 2021-06-09 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-NL579-250mg |
7,10-o-Ditroc docetaxel |
114915-14-9 | 97% | 250mg |
494CNY | 2021-05-08 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-NL579-1g |
7,10-o-Ditroc docetaxel |
114915-14-9 | 97% | 1g |
1312CNY | 2021-05-08 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-NL579-100mg |
7,10-o-Ditroc docetaxel |
114915-14-9 | 97% | 100mg |
251CNY | 2021-05-08 | |
| Chemenu | CM195411-1g |
7,10-O-ditroc docetaxel |
114915-14-9 | 97% | 1g |
$117 | 2022-06-14 |
7,10-o-Ditroc docetaxel Suppliers
Audited Supplier
7,10-o-Ditroc docetaxel Related Literature
-
Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
-
A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
Additional information on 7,10-o-Ditroc docetaxel
7,10-O-Ditroc Docetaxel: A Promising Anticancer Agent with CAS No 114915-14-9
The compound 7,10-O-Ditroc Docetaxel, identified by the CAS registry number CAS No 114915-14-9, has emerged as a significant advancement in the field of oncology. This compound is a derivative of docetaxel, a well-known chemotherapeutic agent used in the treatment of various cancers. The introduction of the 7,10-O-ditroc moiety into the structure of docetaxel has been shown to enhance its pharmacological properties, making it a promising candidate for targeted cancer therapy.
Docetaxel functions by stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. However, its efficacy is often limited by resistance mechanisms and systemic toxicity. The modification of docetaxel to form 7,10-O-Ditroc Docetaxel aims to address these challenges by improving drug delivery and selectivity. Recent studies have demonstrated that this derivative exhibits enhanced antiproliferative activity against various cancer cell lines compared to the parent compound.
The synthesis of CAS No 114915-14-9 involves a multi-step process that includes the introduction of the ditrocarbonyl group at positions 7 and 10 of the docetaxel molecule. This modification not only alters the physicochemical properties of the drug but also influences its interaction with cellular components. Preclinical studies have shown that 7,10-O-Ditroc Docetaxel has improved solubility and bioavailability, which are critical factors for effective drug delivery.
In terms of pharmacokinetics, CAS No 114915-14-9 demonstrates favorable absorption and distribution profiles. Animal studies have revealed that the compound achieves higher concentrations in tumor tissues compared to normal tissues, suggesting a potential reduction in systemic toxicity. This selective accumulation is attributed to the enhanced permeability and retention (EPR) effect, which is particularly advantageous for targeting solid tumors.
The antitumor activity of 7,10-O-Ditroc Docetaxel has been extensively studied in preclinical models. In vitro assays have shown significant inhibition of cell proliferation in breast, lung, and prostate cancer cell lines. Moreover, in vivo studies using xenograft models have demonstrated tumor growth inhibition rates superior to those observed with conventional docetaxel therapy. These findings underscore the potential of this compound as a next-generation anticancer agent.
One of the most exciting aspects of CAS No 114915-14-9 is its ability to overcome drug resistance mechanisms. Many cancers develop resistance to conventional chemotherapeutic agents through mechanisms such as efflux pump upregulation or mutations in target proteins. Early evidence suggests that 7,10-O-Ditroc Docetaxel may bypass these resistance pathways, offering hope for patients with refractory cancers.
The development of CAS No 1149836866666666No 8368666666No 8368666No 8368No 83No 8No
